Project Grant R01CA298815
Award Date
8/1/25
Completion Date
7/31/30
Dollars Obligated
$615K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...
The National Cancer Institute (NCI) awarded a $222,998 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of California, San Diego (UCSD) for the period of March 10, 2025 to February 28, 2027. The grant supports research to engineer endogenous immune cells, including T cells, NK cells, and macrophages, to express chimeric antigen receptors (CARs) using a novel virus-like particle (VLP) vector. The goal is to enable these engineered immune cells to mediate...
This federal Project Grant award of $590,625 from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports research at the University of California, Davis (UC Davis) to develop a novel therapeutic strategy targeting mutant p53 in triple negative breast cancers (TNBCs). The key objectives are to: 1) determine how mutant p53 expression is regulated by the CDK4/6-RBM38-eIF4G axis and the role of mutant p53 as a target of CDK4/6 inhibitors to suppress...
This $379,981 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a localized cancer immunotherapy using particle-anchored cytokines for prolonged intratumoral retention. The primary objectives are to: (I) develop liposome-anchored cytokines with extended tumor retention and minimal systemic leakage, and (II) elucidate the mechanisms by which particle-anchored cytokines elicit durable anti-tumor immunity to improve efficacy in poorly...
This Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) provides $650,450 to the University of Southern California to develop a novel cancer immunotherapy using genetically engineered CD4+ T cells targeting the CT83 tumor antigen. The research aims to determine the mechanisms by which these engineered T cells eliminate lung cancer cells, produce GMP-grade master cell banks and viral particles, and develop a scalable...
This Project Grant award of $676,567.00 was provided by the National Cancer Institute (NCI), under the federal Cancer Treatment Research program (CFDA 93.395), to The Regents of the University of California, San Francisco (UCSF). The award will fund a multi-year research project to systematically test a transforming growth factor beta (TGFB) targeted theranostic radiopharmaceutical therapy approach across preclinical cancer models. The research aims to assess the biological effectiveness of...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $647,632 to the University of California, Los Angeles (UCLA) to research and develop "TNF-ALPHA-'ARMED' TCR VECTORS TO ENHANCE ADOPTIVE CELL THERAPY FOR SOLID TUMORS". The project aims to generate and evaluate novel lentiviral vectors that co-express tumor antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) along with the cytokine tumor necrosis...
This $693,880 Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) supports the development of a novel cancer immunotherapy approach using engineered CD4+ T cells. The goal is to create CD4+ T cells that can target the tumor microenvironment and overcome resistance to current immune checkpoint inhibitor therapies. Key elements include: Identifying key molecules and immune cell targets of the engineered CD4+ T cells in preclinical cancer...